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Abstract 
BACKGROUND Secretory leukocyte protease inhibitor (SLPI) and elafin are anti-protease 
and anti-microbial molecules with a role in innate immune defence. They have been 
demonstrated at multiple mucosal surfaces including those of the female reproductive tract. 
METHODS AND RESULTS This study details their expression in human Fallopian tubes 
(ampullary region) throughout the menstrual cycle (n = 18) and from women with ectopic 
pregnancy (n = 6), and examined their regulation by infection with Chlamydia trachomatis in 
an in-vitro model. Quantitative real-time PCR analysis showed that SLPI and elafin were 
constitutively expressed in the Fallopian tube during the menstrual cycle but were increased 
in ectopic pregnancy (P < 0.05 versus early-mid luteal phase, P < 0.01 versus all phases, 
respectively). SLPI and elafin were immunolocalised to the Fallopian tube epithelium in 
biopsies from non-pregnant women and those with ectopic pregnancy. An in-vitro culture 
model of C. trachomatis infection of the OE-E6/E7 oviductal epithelial cell line showed that 
elafin mRNA expression was upregulated in response to chlamydial infection. 
CONCLUSION These data suggest that SLPI and elafin have a role in the innate immune 
defence of the Fallopian tube in infection and ectopic pregnancy. Their role is likely to 
include regulation of protease activity, wound healing and tissue remodelling. 
 
 
 
 
 
 
 
Introduction 
The female reproductive tract must allow fertilisation, implantation and pregnancy to occur 
while maintaining the ability to respond to infection. Genital tract infection is associated with 
infertility, ectopic pregnancy and preterm labour and the innate immune response is an 
important component of the mucosal defence system (Horne et al., 2008). 
Natural antimicrobial molecules are effectors of the innate immune system and are widely 
expressed throughout the female reproductive tract. Secretory leukocyte protease inhibitor 
(SLPI) and elafin are anti-protease molecules, which also have antimicrobial activity 
(Hiemstra et al., 1996,Sallenave, 2002, Simpson et al., 1999, Simpson et al., 2001, Tomee et 
al., 1998, Wiedow et al., 1998). SLPI inhibits several serine proteases including neutrophil 
elastase and cathepsin G (Thompson and Ohlsson, 1986) while elafin shows a more restricted 
activity, inhibiting only neutrophil elastase and proteinase 3 (Sallenave and Ryle, 
1991, Wiedow et al., 1991, Wiedowet al., 1990). In addition to their anti-protease and anti-
microbial roles, SLPI and elafin are reported to have a range of other anti-inflammatory 
properties, such as an ability to inhibit the nuclear factor-kappa B signalling pathway and 
modulation of the response to lipopolysaccharide (LPS) (Jin et al., 1997, Sallenave et al., 
2003). We have previously reported that SLPI and elafin are expressed in human 
endometrium where they are regulated in a cycle dependent manner and our previous studies 
have also shown that SLPI is a progesterone regulated gene (King et al., 2000, Kinget al., 
2003b, King et al., 2003c). SLPI is expressed in endometrium from the mid-late secretory 
phase of the menstrual cycle when it is localised predominantly to the glandular epithelium 
(King et al., 2000). Expression is maintained in early pregnancy although localisation shifts 
to the decidualised stroma. In contrast, elafin is expressed primarily in endometrial 
neutrophils during menstruation (King et al., 2003b). Both molecules have also been reported 
to be present in cervix and vagina (Fichorova and Anderson, 1999, Moriyama et al., 
1999, Narvekar et al., 2007, Pfundt et al., 1996, Valore et al., 2006) and in addition, SLPI has 
been shown to be present in human Fallopian tube where it is suggested to have a role in the 
protection of sperm from elastase (Ota et al., 2002a). There are no studies documenting the 
expression of SLPI and elafin in Fallopian tube from different menstrual cycle phases. 
The Fallopian tube is the most common site of ectopic pregnancy with over 98% of such 
pregnancies occurring in the oviduct (Lemus, 2000). Early pregnancy bleeding as a result of 
ruptured tubal pregnancy remains one of the commonest causes of maternal death during the 
first trimester of pregnancy (Farquhar, 2005). The pathology underlying ectopic pregnancy is 
unclear although previous infection with Chlamydia trachomatis is a risk factor (Faro, 
1991, Farquhar, 2005). The role of the innate immune system in chlamydial infection and 
ectopic pregnancy is not well understood. We have previously documented increased SLPI 
mRNA expression in the decidualised endometrium of women with ectopic pregnancy 
(Dalgetty et al., 2008). However, there are no studies examining localisation and expression 
of SLPI and elafin in the Fallopian tube during ectopic pregnancy. 
The aim of the current study was to examine the localisation and regulation of SLPI and 
elafin in the Fallopian tube from different menstrual cycle phases and in ectopic pregnancy 
and to examine regulation of SLPI and elafin during in vitro chlamydial infection of an 
oviductal cell line. 
 
Methods 
Tissue collection 
Ethical approval for this study was obtained from Lothian Research Ethics Committee 
(04/S1103/20). All women were aged 18–45 years (mean 38). Written and informed consent 
was obtained from all patients before sample collection. Fallopian tube biopsies (all from 
ampullary region), endometrial biopsies (for histological dating) and sera (for measurement 
of circulating estradiol and progesterone concentrations for endocrine staging) were collected 
from women with regular menstrual cycles (21–35 days) undergoing gynecological 
procedures for benign conditions who had no previous history of ectopic pregnancy and had 
not taken any hormonal preparations in the three months prior to surgery (n = 18; mean age 
39 years; see Table I). Fallopian tube was also obtained from women undergoing surgical 
management of tubal ectopic pregnancy (n = 6; mean age 37 years, mean gestation 58.09 
days ± SD 8.28, mean serum progesterone 58.53 nmol/L ± SD 47.22). None of the women 
undergoing surgical management of ectopic pregnancy presented acutely with haemodynamic 
shock, and all required serial serum beta-HCG and ultrasound monitoring prior to diagnosis. 
Part of the Fallopian tube was immersed in RNAlater™ (Ambion, Texas, USA) at 4°C 
overnight then flash frozen at −70°C, and part of the Fallopian tube and the endometrial 
biopsies were fixed in 10% neutral buffered formalin overnight at 4°C, stored in 70% 
ethanol, and wax embedded. The endometrial biopsies underwent haematoxylin and eosin 
staining and dating by an expert histopathologist. 
 
Quantitative RT-PCR 
RNA was extracted from cells/tissues as detailed in the manufacturer's protocol (Qiagen, 
RNeasy mini kits). All samples were treated with DNase I (Qiagen) in order to remove any 
contaminating genomic DNA. Quantitative real-time RT-PCR was used to measure mRNA 
levels of SLPI and elafin. Complementary DNA (cDNA) was prepared in 20 µl reaction 
volumes containing: 1xRT buffer, magnesium chloride, dNTPs, random hexamers, RNase 
inhibitor and Multiscribe reverse transcriptase (Applied Biosystems, Cheshire, UK). 200 ng 
of template RNA were reverse transcribed and each cDNA experiment included two controls: 
one containing template RNA but no reverse transcriptase (RT negative) and the other 
containing reverse transcriptase with water in place of template RNA (RT H2O). 
PCR reaction mixtures contained Taqman 2x Master-mix (1x; Applied Biosystems), forward 
and reverse primers (300 nM; Eurogentec) and probe (200 nM; Eurogentec) for SLPI or 
elafin and forward and reverse primers and probe for ribosomal 18S (all 50 nM; Applied 
Biosystems). Ribosomal 18S was used as a housekeeping gene. Internal control (SLPI, liver; 
elafin, menstrual endometrium) and negative control (water in place of cDNA) samples were 
included in each PCR run along with the RT negative and RT H2O control samples described 
above. All samples were analysed in triplicate using the 2
–ΔΔCt
 method. PCR reactions were 
run on an ABI 7900 Sequence Detection System (Perkin-Elmer Applied Biosystems, USA). 
SLPI and elafin primers and probes were designed using Primer Express software and their 
sequences have been reported previously (Dalgetty et al., 2008). 
Immunohistochemistry 
Immunohistochemical localisation of SLPI and elafin was performed on Fallopian tube 
sections using standard protocols. In brief, tissue sections were dewaxed in xylene and 
rehydrated in descending grades of alcohol. Sections were microwaved for 15 minutes in 
antigen unmasking solution (Vector) and then non-specific endogenous peroxidase activity 
was blocked with 3% hydrogen peroxide (Sigma-Aldrich). Sections then underwent avidin, 
biotin (Avidin biotin blocking kit, Vector) and protein blocks (DakoCytomation protein 
block, Dako), each for 10 minutes at room temperature. Sections were incubated overnight at 
4°C with either mouse-anti SLPI (1:100; Hycult) or rabbit anti-elafin (1:600, kind gift from 
Jean-Michel Sallenave) (Sallenave et al., 1994) antibody diluted in Dako REAL antibody 
diluent (Dako). In negative control sections, the primary antibody was substituted with mouse 
immunoglobulin (Ig)G (SLPI) or antibody diluent (elafin). Sections were subsequently 
incubated with biotinylated horse anti-mouse or goat anti-rabbit Ig and were then subjected to 
an avidin biotin peroxidase detection system (both for 30 minutes at room temperature; 
Vectastain Elite ABC, Vector). Positive staining was detected using the peroxidase substrate, 
diaminobenzidine (ImmPACT DAB; Vector). Sections were counterstained with Harris' 
haematoxylin, dehydrated in ascending grades of ethanol and mounted from xylene in Pertex. 
 
C. trachomatis detection in fallopian tube biopsies by PCR 
All Fallopian tube biopsies included in this study were screened for current chlamydial 
infection by PCR. DNA was extracted from whole Fallopian tube biopsies from the 
ampullary region of the tube, as detailed in the manufacturers' protocol (Qiagen, West 
Sussex, UK). The PCR protocol used a well-validated, in-house, plasmid-based methodology 
(kindly developed and designed by the West of Scotland Specialist Virology Centre). 
Cell culture 
The OE-E6/E7 oviductal epithelial cell line (a gift from the University of Hong Kong) (Lee et 
al., 2001) was used in an in vitro model of chlamydial infection. Cells were maintained in 
Dulbecco's modified Eagle's medium F12 (Invitrogen) containing 10% fetal calf serum. Cells 
were plated in 48 well culture plates at a density of 2 × 10
5
 cells/well. Prior to treatment cells 
were serum starved overnight and then washed with phosphate-buffered saline. Treatments 
were then applied in a 500 µl volume and performed in triplicate. Cells were exposed to 
live C. trachomatis at multiplicities of infection of 0.001, 0.01 and 0.1 for 4, 24 and 48 hours. 
To control for the presence of modulatory factors in the C. trachomatisstock and in the 
oviductal cell lysate resulting from infection, cells were also exposed to UVC-
irradiated C. trachomatis stock and cell lysate, respectively. Uninfected cells and cells treated 
with LPS from Salmonella minnesota were included as additional controls. Cells were 
collected at each time point for subsequent RNA extraction and analysis of SLPI and elafin 
mRNA expression by real-time quantitative RT-PCR (as detailed above). 
Statistical analysis 
Data were logarithmically transformed prior to statistical analysis. Significant difference was 
determined by one-way analysis of variance and Tukey's posthoc analysis. A P < 0.05 was 
considered statistically significant. 
 
 
 
Results 
Expression of SLPI and elafin mRNA in fallopian tube during the menstrual cycle and in 
ectopic pregnancy 
SLPI mRNA was expressed in Fallopian tube biopsies from throughout the menstrual cycle 
and did not vary at different cycle phases. The presence of ectopic pregnancy significantly 
increased expression of SLPI mRNA compared to the early-mid luteal phase of the menstrual 
cycle (Fig. 1a: P< 0.05). 
Elafin mRNA expression was very low in Fallopian tubes from non-pregnant women and 
expression did not vary at different cycle phases. Ectopic pregnancy resulted in increased 
elafin mRNA expression in the Fallopian tube (Fig. 1b: P < 0.01). 
 
Immunohistochemical localisation of SLPI and elafin in fallopian tube during the 
menstrual cycle and in ectopic pregnancy 
SLPI was localised to the epithelium of all Fallopian tubes collected during the follicular 
phase of the menstrual cycle (all five cases) (Fig. 2a). Epithelial staining was also present in 
some Fallopian tubes (two out of five cases) from the early to mid-luteal (Fig. 2b) and late 
luteal-menstrual phases (two out of three cases). In the Fallopian tube from women with 
ectopic pregnancies, the localisation was similarly epithelial (Fig. 2c). 
Elafin was also localised to the epithelium of Fallopian tubes from all cycle phases (Fig. 2d & 
e). In addition, in some Fallopian tube biopsies from ectopic pregnancy elafin was localised 
to leukocytes present in blood vessels within the mucosal layer (Fig. 2f). 
 
Detection of current chlamydial infection in fallopian tube biopsies 
All Fallopian tube biopsies were screened for current C. trachomatisinfection by PCR and 
shown to be negative (data not shown). 
 
Regulation of SLPI and elafin MRNA expression in an in vitro model 
of c.trachomatis infection 
Infection of the OE-E6/E7 oviductal epithelial cell line with C. trachomatishad no effect on 
SLPI mRNA expression at 4 (data not shown), 24 and 48 hr time points (Fig. 3a). In contrast, 
elafin mRNA expression was increased by the highest dose of C. trachomatis at 24 hours 
(P < 0.05; Fig. 3b). There were no significant changes in elafin mRNA expression at 4 (data 
not shown) or 48 hours (Fig. 3b). 
 
Discussion 
In this study we have shown that the anti-protease and anti-microbial molecules, SLPI and 
elafin, are expressed in the epithelial layer of the human Fallopian tube throughout the 
menstrual cycle. Both molecules are present at other mucosal layers, such as the lung 
(Franken et al., 1989,Sallenave et al., 1992) and they are also widely expressed at 
reproductive sites including the vagina, cervix and endometrium, where they contribute to the 
innate immune response (Horne et al., 2008). The presence of SLPI and elafin in the 
Fallopian tube suggests that they also have an innate immune role at this upper genital tract 
site, where they may protect against ascending infection and regulate associated 
inflammatory events. A previous study has suggested that the anti-protease actions of SLPI in 
the Fallopian tube may protect sperm from the detrimental effects of elastase (Ota et al., 
2002b) suggesting that SLPI and elafin may also modulate inflammatory events occurring at 
fertilisation which may be detrimental to sperm and the developing embryo. 
We have shown that SLPI and elafin are not regulated in a cycle dependent manner at the 
mRNA level in the Fallopian tube. This is in contrast to our previous studies in endometrium, 
which have shown SLPI to be maximally expressed in the secretory phase of the menstrual 
cycle (King et al., 2000) and elafin expression to peak at menstruation (King et al., 2003b). 
These differences in regulation of the molecules at two upper genital tract sites may reflect 
the different functions of the Fallopian tube and endometrium. The endometrium undergoes 
repeat cycles of proliferation, differentiation and repair in response to changes in the levels of 
circulating steroid hormones (Jabbour et al., 2006). It must allow the breaching of the 
mucosal barrier at implantation and menstruation while maintaining the ability to mount an 
innate immune response if necessary. Increased natural antimicrobial expression during the 
implantation window and at menstruation may be one mechanism for enhancing innate 
immune protection at these vulnerable times (King et al., 2003a). In contrast, the Fallopian 
tube undergoes relatively few cycle dependent changes and the epithelial layer is not 
normally breached, and the constant expression of SLPI and elafin may reflect this. 
Ectopic implantation occurs most commonly in the Fallopian tube (Lemus, 2000) although 
few studies have examined the molecular changes that predispose to or result from 
inappropriate implantation. In the current study we document increased mRNA expression of 
both SLPI and elafin in the Fallopian tube from ectopic pregnancies. Due to ethical 
constraints it is not possible to obtain Fallopian tubes from women with intrauterine 
pregnancies and thus, it is not clear whether the increased expression of SLPI and elafin are a 
result of the systemic hormonal environment created by pregnancy or the local inflammatory 
changes that accompany ectopic pregnancy or prior tubal infection. Our previous studies have 
shown that SLPI is a progesterone responsive gene (King et al., 2003c) and the increased 
mRNA expression present in the Fallopian tube in ectopic pregnancy may reflect high 
circulating progesterone levels. While histological studies suggest there is little evidence for 
acute inflammatory changes at the site of an ectopic pregnancy (Kutluay et al., 1994), recent 
studies at the molecular level suggest that there are inflammatory changes. Disruption of the 
interleukin (IL)-1 signalling system is reported to occur in Fallopian tube with ectopic 
pregnancy (Huang et al., 2005) and expression of leukaemia inhibitory factor, a cytokine 
known to have a crucial role in uterine implantation, is reported to be increased in tubal 
pregnancy (Ji et al., 2008). Elafin and, to a lesser extent, SLPI are upregulated by 
inflammatory stimuli, including IL-1 (King et al., 2003c,Sallenave et al., 1994, Williams et 
al., 2006), and a shift towards a pro-inflammatory environment may result in their increased 
expression in ectopic pregnancy. Previous infection with C. trachomatis is a risk factor for 
ectopic pregnancy and we have shown that elafin is upregulated in an oviduct epithelial cell 
line in response to chlamydial infection in vitro. These data suggest 
that C. trachomatis infection may contribute to the raised mRNA expression of elafin in 
ectopic pregnancy. The women recruited to this study were not currently infected 
by C. trachomatis but it is possible that they may previously have been infected 
with Chlamydia. This would require further serological analysis for IgG antibodies or 
chlamydial heat-shock protein 60 and may be important, as the link 
between C. trachomatis and ectopic pregnancy is mainly based on early seroepidemiological 
case-control studies (Bakken, 2008). 
However, if C. trachomatis and ectopic pregnancy are linked, the role of SLPI and elafin 
in C. trachomatis infection and/or ectopic pregnancy is likely to include inhibition of protease 
activity (Thompson and Ohlsson, 1986, Sallenave and Ryle, 1991, Wiedow et al., 
1991, Wiedow et al., 1990), promotion of wound healing (Ashcroft et al., 2000) and tissue 
remodelling (Lee et al., 2002). These anti-inflammatory actions will limit tissue damage due 
to infection or abnormal implantation. Alternatively, abnormal expression of SLPI and elafin 
may predispose to infection or ectopic pregnancy. Previous studies have suggested that 
changes in the innate immune system are associated with reproductive tract pathologies. 
Women with single nucleotide polymorphisms in two or more of the genes for Toll-like 
receptor (TLR)9, TLR4, CD14 or nucleotide-binding oligomerization domain containing 2 
(NOD2) showed a trend towards increased likelihood of tubal pathology (den Hartog et al., 
2006). Decreased expression of SLPI in vaginal secretions is related to infection of the lower 
genital tract by C. trachomatis, although it is unclear whether this occurs prior to or as a 
result of infection (Draper et al., 2000). Contrary to our findings with OE-E6/E7 cells, 
experimental infection of Hela cells with C. trachomatis results in increased expression of 
SLPI mRNA and SLPI peptide (Wheelhouse et al., 2008). Despite this increase in SLPI 
expression following infection and the fact that HeLa cells constitutively produce SLPI in the 
absence of infection, C. trachomatisgrows well, strongly suggesting that SLPI does not have 
a direct antimicrobial effect on chlamydial growth. 
In summary, we have demonstrated that the anti-protease and anti-microbial molecules SLPI 
and elafin are expressed in human Fallopian tube, that mRNAs for both are upregulated in 
ectopic pregnancy, and mRNA for elafin is increased in response to chlamydial infection in a 
cell culture model. This suggests that SLPI and elafin are involved in the innate immune 
protection of the Fallopian tube during the normal menstrual cycle and may be important in 
the event of pathological conditions, such as infection and ectopic implantation. 
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Legends 
Table I 
Demographics for Fallopian tube and endometrial biopsies from women undergoing surgery 
for benign gynecological conditions 
Figure 1 
Secretory leukocyte protease inhibitor (SLPI) and elafin mRNA expression in the human 
Fallopian tube (ampullary region) during the menstrual cycle and in ectopic pregnancy. 
F=follicular phase, EL/ML = early-mid luteal phase, LL/M=late luteal-menstrual phase. (a) 
SLPI mRNA expression. a = P < 0.05 (EL/ML versus ectopic). (b) Elafin mRNA expression. 
ab:P < 0.001 (F and EL/ML versus ectopic), c:P < 0.01 (LL/M versus ectopic). Data are 
mean ± SEM. 
 
Figure 2 
Immunohistochemical localisation of SLPI and elafin in human Fallopian tube (ampullary 
region) during the menstrual cycle and in ectopic pregnancy. (a) SLPI. Follicular phase. (b) 
SLPI. Luteal phase. (c) SLPI. Ectopic. (d) Elafin. Follicular phase. (e) Elafin. Luteal phase. 
(f) Elafin. Ectopic. Negative controls in insets. Scale bar = 100 µm. 
 
Figure 3 
SLPI and elafin mRNA expression in the OE-E6/E7 oviductal epithelial cell line upon 
exposure toChlamydia trachomatis. MOI = multiplicity of infection, UV-C = ultra-violet 
irradiated C. trachomatis (control), Smin LPS = Salmonella minnesotalipopolysaccharide 
(control) (a) SLPI mRNA expression. (b) Elafin mRNA expression. abc:P < 0.05 (infection 
at 24 hours with 0.1 MOI versus media, lysate and Smin LPS controls). Data are mean ± 
SEM. 
 
 
 
 
 
 
 
 
Tab.I 
 
Age 
(years) 
Parity Cycle 
phase 
Serum 
estradiol 
(pmol/L) 
Serum 
Progesterone 
(nmol/L) 
Endometrium Surgery Reason for 
surgery 
Uterine 
pathology 
41 2 Follicular 1022.87 0.81 Proliferative TAH HMB Adenomyosis 
37 2 Follicular 940.44 3.82 Proliferative TAH HMB, pelvic 
pain 
Adenomyosis 
44 3 Follicular 829.42 4.19 Proliferative TAH HMB, pelvic 
pain 
Adenomyosis, 
fibroid 
36 3 Follicular 770.63 5.16 Proliferative TAH HMB No 
abnormality 
44 2 Follicular 116.3 2.88 Proliferative STAH HMB, 
dysmenorrhoea 
No 
abnormality 
40 5 Early 
luteal 
255 49.05 Early 
secretory 
TAH HMB, 
dysmenorrhoea 
No 
abnormality 
43 2 Early-mid 
luteal 
399.8 80.45 Early 
secretory 
TAH HMB, 
dysmenorrhoea 
Adenomyosis, 
polyp, fibroid 
34 2 Mid luteal 471 62.65 Mid secretory LAVH HMB, 
dysmenorrhoea 
Adenomyosis, 
polyp, fibroid 
40 2 Mid luteal 242 53.1 Mid secretory TAH HMB, 
dysmenorrhoea 
No 
abnormality 
35 2 Mid luteal 424 76.9 Mid secretory TAH pelvic pain No 
abnormality 
38 3 Mid luteal 266 37.1 Mid secretory TAH HMB No 
abnormality 
32 1 Mid luteal 549.91 88 Mid secretory TAH Dysmenorrhoea 
 
No 
abnormality 
43 2 Mid luteal 201 24.55 Mid secretory TAH HMB, pelvic 
pain 
Fibroid 
40 1 Mid luteal 1633.0 54.38 Mid secretory TAH HMB, 
dysmenorrhoea 
No 
abnormality 
37 2 Late luteal 392.18 3.06 Late secretory TAH Dysmenorrhoea No 
abnormality 
43 2 Late luteal 274 35.8 Late secretory TAH HMB Fibroids 
35 4 Menstrual 73 2.67 Menstrual TAH HMB, 
dysmenorrhoea 
Adenomyosis 
42 2 Menstrual 55 15.05 Menstrual TAH HMB No 
abnormality 
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